- Third Wave Technologies, Inc. reported a net loss of $4.7 million, or 11 cents a share, for the second quarter of 2006, but robust sales have prompted the company to revise year-end revenue projections upward in a key market.
Third Wave, which develops molecular diagnostic reagents for DNA and RNA analysis applications, reported that revenue rose by 15 p......Full article >>>
the second quarter, compared to $11.5 million for the same period of 2005. Third Wave's pro forma total operating expenses for the second quarter of 2005, including stock compensation costs, were $13.2 million.
For the first six months of 2006, total operating expenses were $24.4 million, compared to $23.1 million for the same period of 2005. The company's pro forma total operating expens......Full article >>>
tection of chlamydia and gonorrhea in 2007. Testing for HPV, chlamydia, and gonorrhea accounts for more than 20 percent of the molecular diagnostic testing market.
As a result, Third Wave has raised its projection on clinical molecular diagnostic revenue to $20-21 million for 2006.
Another new product is a next generation version of Invader. Based on the results of external evalu......Full article >>>
Source:wistechnology.com By Joe Vanden Plas 07/25/06Related biology technology :1
. Third Wave files countersuit vs. Digene in patent case2
. Third Wave reports net loss of $18.9M for 20063
. Stratagene to pay Third Wave $10.75M in patent case4
. Third Wave responds to Digene patent lawsuit5
. Third Wave seeks approval of Cystic Fibrosis test6
. Third Wave Technologies to raise $14.9M through private debt7
. Third Wave reports $5.2M third quarter loss8
. Napier joins board of Third Wave Technologies9
. Third Waves revenues rebound10
. Third Wave reports clinical growth, continued loss11
. Third Wave announces two senior management appointments